Código QR (código de barras bidimensional)

Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

Abstract Mesenchymal–epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%–4%) driver mutation in non‐small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping‐mutated NSCLC. However, its feasibility for perioperative...

תיאור מלא

שמור ב:
Principais autores: Rongzhen Li, Xiaoyan Liu, Yan Xu, Jing Zhao, Wei Zhong, Xiaoxing Gao, Minjiang Chen, Mengzhao Wang
פורמט: Artigo
שפה:Inglês
יצא לאור: Wiley 2024-11-01
סדרה:Thoracic Cancer
נושאים:
MET exon 14 skipping mutation
neoadjuvant
non‐small cell lung cancer
tepotinib
גישה מקוונת:https://doi.org/10.1111/1759-7714.15459
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים